Literature DB >> 14988673

Innate immune defense of the nail unit by antimicrobial peptides.

Robert A Dorschner1, Belen Lopez-Garcia, Jennifer Massie, Choll Kim, Richard L Gallo.   

Abstract

BACKGROUND: The nail is susceptible to microbial invasion, yet is usually able to defend itself from infection. This occurs despite isolation from cell-mediated immunity.
OBJECTIVE: The aim of this study was to determine whether soluble innate immune molecules are present in the nail environment that can protect against microbial colonization.
METHODS: Chromatographic techniques were used to purify cationic antimicrobial molecules from porcine hoof extracts. Sections of human and mouse digits were immunostained with antibodies to each species' cathelicidin antimicrobial peptide. Liquid antimicrobial assays were used to determine the activity of these molecules against relevant pathogens.
RESULTS: Human, porcine, and murine nails contain antimicrobial molecules, and the human cathelicidin LL-37 can kill Candida albicans.
CONCLUSION: The presence of antimicrobial peptides in nails with activity against relevant nail pathogens may account for the ability of the nail unit to resist infection in the absence of direct access to the cellular immune system.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14988673     DOI: 10.1016/j.jaad.2003.09.010

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  10 in total

Review 1.  Keratinocytes: An Enigmatic Factor in Atopic Dermatitis.

Authors:  Pamelika Das; Pappula Mounika; Manoj Limbraj Yellurkar; Vani Sai Prasanna; Sulogna Sarkar; Ravichandiran Velayutham; Somasundaram Arumugam
Journal:  Cells       Date:  2022-05-19       Impact factor: 7.666

Review 2.  Antimicrobial peptides, skin infections, and atopic dermatitis.

Authors:  Tissa R Hata; Richard L Gallo
Journal:  Semin Cutan Med Surg       Date:  2008-06

Review 3.  Updating corneofungimetry: a bioassay exploring dermatomycoses and antifungal susceptibility.

Authors:  Gérald E Piérard; Claudine Piérard-Franchimont; Pascale Quatresooz
Journal:  Mycopathologia       Date:  2010-01       Impact factor: 2.574

Review 4.  Candidal onychomycosis: a mini-review.

Authors:  J A M S Jayatilake; W M Tilakaratne; G J Panagoda
Journal:  Mycopathologia       Date:  2009-05-31       Impact factor: 2.574

Review 5.  Antimicrobial peptides in human skin disease.

Authors:  Kenshi Yamasaki; Richard L Gallo
Journal:  Eur J Dermatol       Date:  2007-12-18       Impact factor: 3.328

6.  Tazarotene as alternative topical treatment for onychomycosis.

Authors:  Elena Campione; Evelin Jasmine Paternò; Gaetana Costanza; Laura Diluvio; Isabella Carboni; Daniele Marino; Cartesio Favalli; Sergio Chimenti; Luca Bianchi; Augusto Orlandi
Journal:  Drug Des Devel Ther       Date:  2015-02-16       Impact factor: 4.162

7.  Improved Methods for Assessing Therapeutic Potential of Antifungal Agents against Dermatophytes and Their Application in the Development of NP213, a Novel Onychomycosis Therapy Candidate.

Authors:  Derry K Mercer; Colin S Stewart; Lorna Miller; Jennifer Robertson; Vanessa M S Duncan; Deborah A O'Neil
Journal:  Antimicrob Agents Chemother       Date:  2019-04-25       Impact factor: 5.191

Review 8.  Innate Inspiration: Antifungal Peptides and Other Immunotherapeutics From the Host Immune Response.

Authors:  Derry K Mercer; Deborah A O'Neil
Journal:  Front Immunol       Date:  2020-09-17       Impact factor: 7.561

9.  NP213 (Novexatin®): A unique therapy candidate for onychomycosis with a differentiated safety and efficacy profile.

Authors:  Derry K Mercer; Jennifer C Robertson; Lorna Miller; Colin S Stewart; Deborah A O'Neil
Journal:  Med Mycol       Date:  2020-11-10       Impact factor: 4.076

Review 10.  Overview of the molecular determinants contributing to the expression of Psoriasis and Psoriatic Arthritis phenotypes.

Authors:  Valerio Caputo; Claudia Strafella; Andrea Termine; Annunziata Dattola; Sara Mazzilli; Caterina Lanna; Terenzio Cosio; Elena Campione; Giuseppe Novelli; Emiliano Giardina; Raffaella Cascella
Journal:  J Cell Mol Med       Date:  2020-10-31       Impact factor: 5.295

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.